人工智能驱动的超长作用GLP-1受体激动剂的De Novo设计
Ting Wei1, Jiating Ma1, Xiaochen Cui2
1State Key Laboratory of Microbial Metabolism, Department of Bioinformatics and Biostatistics, SJTU-Yale Joint Center for Biostatistics, National Experimental Teaching Center for Life Sciences and Biotechnology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.
这项研究引入了人工智能驱动的快速类药物设计管道,显著提高了稳定性和有效性. 在临床前模型中,新型葡萄糖类-1受体激动剂 (GLP-1RAs) 显示了延长的半衰期和强大的治疗效果.
科学领域:
- 生物技术是生物技术.
- 计算生物学 计算生物学
- 药物发现 药物发现 药物发现
背景情况:
- 类药物具有治疗潜力,但在设计效率,成本和时间方面面临挑战.
- 目前用于类药物设计的方法通常是缓慢和昂贵的,限制了创新.
研究的目的:
- 开发一种高效的AI驱动方法,用于快速设计和发现疗法.
- 创建具有增强稳定性和疗效的新型葡萄糖类-1受体激动剂 (GLP-1RAs).
主要方法:
- 基于深度学习的蛋白质设计与功能选的整合.
- 一万个GLP-1RAs的新设计,随后进行稳定性,有效性和多样性的虚拟查.
- 在糖尿病和肥胖小鼠模型中的体外验证和体内测试.
主要成果:
- 60个设计的GLP-1RA符合虚拟查标准.
- 在体外验证取得了52%的成功率.
- 两个主要候选药物 (D13和D41) 的半衰期比塞马格卢提德的半衰期长三倍,D13在小鼠模型中显示出显著的血糖降低和可比的减肥效果.
结论:
- 人工智能驱动的酸设计管道加速了新候选的发现.
- 这种综合方法大大减少了类药物开发所需的时间和代,在两周内完成了该过程.
更多相关视频
09:31Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
06:34Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: Glinides
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Dipeptidyl Peptidase 4 Inhibitors
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
